GARNET
GARNET showed that the PD-1 antibody dostarlimab produced lasting responses in about four in ten women with mismatch repair-deficient endometrial cancer that had returned after chemotherapy, which won the drug its first approvals.
Overview
GARNET was a large phase 1 dose-finding and expansion study of dostarlimab, a PD-1 antibody, in advanced solid tumours. Its expansion cohorts enrolled recurrent or advanced endometrial cancer after platinum, split by mismatch repair status, and a cohort of non-endometrial mismatch repair-deficient tumours. The primary endpoints for the expansion cohorts were objective response rate and duration of response by independent review.
In the mismatch repair-deficient endometrial cohort roughly four in ten patients responded and most responses were durable, with a lower response rate in the proficient cohort. Dostarlimab received accelerated approval in the United States in April 2021 for mismatch repair-deficient recurrent endometrial cancer and later a tumour-agnostic approval for mismatch repair-deficient solid tumours; the RUBY trial then moved it into first line with chemotherapy.
Similar pages
not linked directly; found by shared links- TrialMOMENTUM
Shares GSK and the tag subtype-trials.
- TrialPORTEC-2
Shares Endometrial cancer and the tag subtype-trials.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Shares Mismatch-repair-deficient endometrial cancer, Dostarlimab, GSK, Endometrial cancer.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer.
- TrialA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Shares Dostarlimab, GSK.
- TrialA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Shares Dostarlimab, GSK.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares Dostarlimab, GSK.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares Dostarlimab, GSK.